Dr. Cavanaugh has supported the biopharma industry for over 10 years. She joined GE Healthcare Life Sciences in 2008 and focused on biomolecular separations. At GE, she held multiple positions of increasing responsibility prior to the spin-off of the Life Sciences business into what is now Cytiva. In her current role, Dr. Cavanaugh leads the strategic alignment between Cytiva and two global pharma organizations, leveraging new technologies and innovation to provide support for the production and development of numerous advanced therapies. Dr. Cavanaugh received a BA from Hunter College, CUNY, and both her MA and Ph.D. in Molecular Biology from Princeton University.